Selected clinical and epidemiological features of tuberculosis coinfection, infection caused by human immunodeficiency virus and viral hepatitis

Abstract

The study estimated the prevalence of human immunodeficiency virus infection and viral hepatitis in patients admitted to the tuberculosis hospital in 2018–2020. Among patients admitted for the treatment of tuberculosis, 36.8% had human immunodeficiency virus infection. Markers of viral hepatitis were also detected in 78.8% of patients with human immunodeficiency virus infection associated with tuberculosis. The most common coinfection was tuberculosis — human immunodeficiency virus–hepatitis C, which was confirmed in 28.2% of the admitted patients. Clinical, X-ray, laboratory, and sonographic indicators were analyzed in 43 patients with tuberculosis having human immunodeficiency virus infection and viral hepatitis in various combinations. All patients were divided into three groups: group 1 included patients with tuberculosis, human immunodeficiency virus infection, and viral hepatitis, group 2 included patients with tuberculosis and human immunodeficiency virus infection, and group 3 included patients with tuberculosis and viral hepatitis. Anti-tuberculosis therapy was prescribed to all patients based on the spectrum of drug sensitivity of Mycobacterium tuberculosis, and when a human immunodeficiency virus infection was detected, antiretroviral therapy was prescribed during the first 2 weeks. Patients with viral hepatitis, if indicated, were prescribed hepatoprotective drugs. Control laboratory tests were conducted once every 2 months or more often in the presence of indications. Groups 1 and 2 were more likely to have multiple organ involvement and generalized forms, which determined the severity of the clinical course. In group 1, the activity of alanine aminotransferase and aspartate aminotransferase exceeded the normal limits upon hospital admission. Bilirubin levels were significantly higher in group 3 than in groups 1 and 2. The analysis of sonographic characteristics revealed increased size of the right liver lobe in all groups, without statistically significant differences between the groups. Adverse hepatotoxic reactions were reported in 5 (33.3%) patients of group 1, 4 (26.6%) of group 2, and 4 (30.7%) of group 3. The main manifestations of these reactions were pain in the right hypochondrium and increased activities of alanine aminotransferase and asparate aminotransferase. Patients with hepatotoxic reactions were prescribed hepatoprotective drugs, which made it possible to avoid the cancellation of complex etiotropic therapy

Keywords

tuberculosis / human immunodeficiency virus / viral hepatitis / markers of viral hepatitis / hepatotoxicity / hepatoprotective drugs / antiretroviral therapy / etiotropic therapy

References

[1] Manina VV, Starshinova AA, Panteleev AM. Tuberculosis and HIV-infection: epidemic situation in Russia and in the world over the past ten years, features of detection and diagnosis. HIV Infection and Immunosuppressive Disorders. 2017;9(4):7–16. (In Russ.).. DOI: 10.22328/2077-9828-2017-9-4-7-16

[2] Манина В.В., Старшинова А.А., Пантелеев А.М. Туберкулез и ВИЧ-инфекция: эпидемическая ситуация в России и в мире за последние десять лет, особенности выявления и диагностики // ВИЧ-инфекция и иммуносупрессии. 2017. Т. 9, № 4. С. 7–16. DOI: 10.22328/2077-9828-2017-9-4-7-16

[3] Komissarova OG, Abdullaev RY, Gerasimov LN, et al. HIV-associated tuberculosis: the course of the tuberculosis process and efficacy of treatment (Review). Ural Medical Journal. 2018;(8):41–46. (In Russ.). DOI: 10.25694/URMJ.2018.05.49

[4] Комиссарова О.Г., Абдуллаев Р.Ю., Герасимов Л.Н., и др. ВИЧ-ассоциированный туберкулез: особенности течения и эффективность лечения (обзор литературы) // Уральский медицинский журнал. 2018. № 8. С. 41–46. DOI: 10.25694/URMJ.2018.05.49

[5] Tsybikovа EB, Son IM, Vlаdimirov AV. Tuberculosis and HIV mortality in Russia. Tuberculosis and Lung Diseases. 2020;98(6): 15–21. (In Russ.). DOI: 10.21292/2075-1230-2020-98-6-15-21

[6] Цыбикова Э.Б., Cон И.М., Владимиров А.В. Смертность от туберкулеза и ВИЧ-инфекции в России // Туберкулез и болезни легких. 2020. Т. 98, № 6. С. 15–21. DOI: 10.21292/2075-1230-2020-98-6-15-21

[7] Belyakov NA, Rassokhin VV, Trofimova TN, et al. Advanced and comorbid HIV cases in Russia. HIV Infection and Immunosuppressive Disorders. 2016;8(3):9–25. (In Russ.). DOI: 10.22328/2077-9828-2016-8-3-9-25

[8] Беляков Н.А., Рассохин В.В., Трофимова Т.Н. и др. Коморбидные и тяжелые формы ВИЧ-инфекции в России // ВИЧ-инфекция и иммуносупрессии. 2016. Т. 8, № 3. С. 9–25. DOI: 10.22328/2077-9828-2016-8-3-9-25

[9] Azovtzeva OV, Panteleev AM, Karpov AV, et al. Analysis of medical and social factors affecting the formation and course of co-infection HIV, tuberculosis and viral hepatitis. Russian Journal of Infection and Immunity. 2019;9(5–6):787–799. (In Russ.). DOI: 10.15789/2220-7619- 2019-5-6-787-799

[10] Азовцева О.В., Пантелеев А.М., Карпов А.В., и др. Анализ медико-социальных факторов, влияющих на формирование и течение коинфекции ВИЧ, туберкулеза и вирусного гепатита // Инфекция и иммунитет. 2019. Т. 9, № 5–6. С. 787–799. DOI: 10.15789/2220-7619-2019-5-6-787-799

[11] Zhdanov KV, Kozlov KV, Shakhmanov DM, et al. Medical assistance to patients with viral hepatitis in the armed forces. Russian military medical journal. 2020;341(11):4–10. (In Russ.).

[12] Жданов К.В., Козлов К.В., Шахманов Д.М., и др. Медицинская помощь больным вирусными гепатитами в Вооруженных Силах // Военно-медицинский журнал. 2020. Т. 341. № 11. С. 4–10.

[13] Bulankov YuI, Bulygin MA, Zhdanov KV, et al. Clinical and epidemiological characteristics of HIV infection in military personnel of the Russian Ministry of Defense as a rationale for optimizing medical care for military personnel. HIV Infection and Immunosuppressive Disorders. 2020;12(4):32–42. (In Russ.). DOI: 10.22328/2077-9828-2020-12-4-32-42

[14] Буланьков Ю.И., Булыгин М.А., Жданов К.В., и др. Клинико-эпидемиологическая характеристика ВИЧ-инфекции у военнослужащих Минобороны России как обоснование направлений оптимизации медицинской помощи военнослужащим // ВИЧ-инфекция и иммуносупрессии. 2020. Т. 12, № 4. С. 32–42. DOI: 10.22328/2077-9828-2020-12-4-32-42

[15] Dolan K, Wirtz AL, Moazen B, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388(10049):1089–1102. DOI: 10.1016/S0140-6736(16)30466-4

[16] Dolan K., Wirtz A.L., Moazen B., et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees // Lancet. 2016. Vol. 388. No. 10049. Р. 1089–1102. DOI: 10.1016/S0140-6736(16)30466-4

[17] Kinner SA, Snow K, Wirtz AL, et al. Age-Specific Global Prevalence of Hepatitis B, Hepatitis C, HIV, and Tuberculosis Among Incarcerated People: A Systematic Review. J Adolesc Health. 2018;62(3S):S18–S26. DOI: 10.1016/j.jadohealth.2017.09.030

[18] Kinner S.A., Snow K., Wirtz A.L., et al. Age-Specific Global Prevalence of Hepatitis B, Hepatitis C, HIV, and Tuberculosis Among Incarcerated People: A Systematic Review // J Adolesc Health. 2018. Vol. 62, No. 3S. P. S18–S26. DOI: 10.1016/j.jadohealth.2017.09.030

[19] Enoh JE, Cho FN, Manfo FP, et al. Abnormal Levels of Liver Enzymes and Hepatotoxicity in HIV-Positive, TB, and HIV/TB-Coinfected Patients on Treatment in Fako Division, Southwest Region of Cameroon. Biomed Res Int. 2020:9631731. DOI: 10.1155/2020/9631731

[20] Enoh J.E., Cho F.N., Manfo F.P., et al. Abnormal Levels of Liver Enzymes and Hepatotoxicity in HIV-Positive, TB, and HIV/TB-Coinfected Patients on Treatment in Fako Division, Southwest Region of Cameroon // Biomed Res Int. 2020. Vol. 2020. P. 9631731. DOI: 10.1155/2020/9631731

[21] Nechaev VV, Ivanov AK, Sacra AA, et al. Chronic viral hepatitis, tuberculosis, and HIV as comorbidity: from theory to practice. Journal Infectology. 2017;9(4):126–132. (In Russ.). DOI: 10.22625/2072-6732-2017-9-4-126-132

[22] Нечаев В.В., Иванов А.К., Сакра А.А., и др. Хронические вирусные гепатиты, туберкулез и ВИЧ-инфекция как сочетанные заболевания: от теории к практике // Журнал инфектологии. 2017. Т. 9, № 4. С. 126–132. DOI: 10.22625/2072-6732-2017-9-4-126-132

[23] Burke RM, Rickman HM, Singh V, et al. What is the optimum time to start antiretroviral therapy in people with HIV and tuberculosis coinfection? A systematic review and meta-analysis. J Int AIDS Soc. 2021;24(7):e25772. DOI: 10.1002/jia2.25772.

[24] Burke R.M., Rickman H.M., Singh V., et al. What is the optimum time to start antiretroviral therapy in people with HIV and tuberculosis coinfection? A systematic review and meta-analysis // J Int AIDS Soc. 2021. Vol. 24, No. 7. P. e25772. DOI: 10.1002/jia2.25772

[25] Kadia BM, Dimala CA, Fongwen NT, et al. Barriers to and enablers of uptake of antiretroviral therapy in integrated HIV and tuberculosis treatment programmes in sub-Saharan Africa: a systematic review and meta-analysis. AIDS Res Ther. 2021;18(1):85. DOI: 10.1186/s12981-021-00395-3

[26] Kadia B.M., Dimala C.A., Fongwen N.T., et al. Barriers to and enablers of uptake of antiretroviral therapy in integrated HIV and tuberculosis treatment programmes in sub-Saharan Africa: a systematic review and meta-analysis // AIDS Res Ther. 2021. Vol. 18, Nо. 1. P. 85. DOI: 10.1186/s12981-021-00395-3

[27] Arora U, Garg P, Agarwal S, et al. Complexities in the treatment of coinfection with HIV, hepatitis B, hepatitis C, and tuberculosis. Lancet Infect Dis. 2021;21(12):e399–e406. DOI: 10.1016/ S1473-3099(20)30765-9

[28] Arora U., Garg P., Agarwal S., et al. Complexities in the treatment of coinfection with HIV, hepatitis B, hepatitis C, and tuberculosis // Lancet Infect Dis. 2021. Vol. 21, Nо. 12. P. e399–e406. DOI: 10.1016/S1473-3099(20)30765-9

[29] Cerrone M, Bracchi M, Wasserman S, et al. Safety implications of combined antiretroviral and anti-tuberculosis drugs. Expert Opin Drug Saf. 2020;19(1):23–41. DOI: 10.1080/14740338.2020.1694901

[30] Cerrone M., Bracchi M., Wasserman S., et al. Safety implications of combined antiretroviral and anti-tuberculosis drugs // Expert Opin Drug Saf. 2020. Vol. 19, Nо. 1. P. 23–41. DOI: 10.1080/14740338.2020.1694901

[31] Ivanova DА, Borisov SE, Rodina OV, et al. Safety of treatment regimens in multiple drug resistant tuberculosis patients compiled as per the new WHO recommendations as of 2019. Tuberculosis and Lung Diseases. 2020;98(1):5–15. (In Russ.). DOI: 10.21292/2075-1230-2020-98-1-5-15

[32] Иванова Д.А., Борисов С.Е., Родина О.В., и др. Безопасность режимов лечения больных туберкулезом с множественной лекарственной устойчивостью возбудителя согласно новым рекомендациям ВОЗ 2019 г. // Туберкулёз и болезни лёгких. 2020. Т. 98, № 1. С. 5–15. DOI: 10.21292/2075-1230-2020-98-1-5-15

[33] Mo P, Zhu Q, Teter C, еt al. Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus. Int. J. Infect. Dis. 2014;28:95–100. DOI: 10.1016/j.ijid.2014.06.020

[34] Mo P., Zhu Q., Teter C., еt al. Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus // Int J Infect Dis. 2014. Vol. 28. P. 95–100. DOI: 10.1016/j.ijid.2014.06.020

[35] Sekaggya-Wiltshire C, von Braun A, Scherrer AU, et al. Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients. J Antimicrob Chemother. 2017;72(4):1172–1177. DOI: 10.1093/jac/dkw534

[36] Sekaggya-Wiltshire C., von Braun A., Scherrer A.U., et al. Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients // J Antimicrob Chemother. 2017 Vol. 72, Nо. 4. P. 1172–1177. DOI: 10.1093/jac/dkw534

[37] Sukach M. Risk factors of hepatotoxicity after antituberculosis treatment in patients with triple infection (tuberculosis, HIV-infection, hepatitis C). Clinical infectology and parasitology. 2016;5(4):449–458. (In Russ.).

[38] Сукач М.Н. Факторы риска гепатотоксичности при проведении противотуберкулезного лечения у больных, коинфицированных ВИЧ и хроническим гепатитом С // Клиническая инфектология и паразитология. 2016. Т. 5, № 4. С. 449–458.

[39] Ivаnovа DA, Borisov SE. To discontinue or to wait? Indications for discontinuation of anti-tuberculosis drugs due to adverse events. Tuberculosis and Lung Diseases. 2018;96(2):47–54. (In Russ.). DOI: 10.21292/2075-1230-2018-96-2-47-54

[40] Иванова Д.А., Борисов С.Е. Отменить или подождать? Показания к отмене противотуберкулезных препаратов при нежелательных реакциях // Туберкулез и болезни легких. 2018. Т. 96, № 2. С. 47–54. DOI: 10.21292/2075-1230-2018-96-2-47-54

RIGHTS & PERMISSIONS

Eco-Vector